title: No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
authors.forename: C
authors.initials: C
authors.lastname: Simonelli
authors.forename: M
authors.initials: M
authors.lastname: Comar
authors.forename: S
authors.initials: S
authors.lastname: Zanussi
authors.forename: P
authors.initials: P
authors.lastname: De Paoli
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: M
authors.initials: M
authors.lastname: Giacca
mesh_terms: D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D012367:RNA, Viral; D015215:Zidovudine; D016049:Didanosine; D006918:Hydroxyurea